Cancer drug companies are racing to develop the next big immuno-oncology drugs, and Bristol Myers Squibb Company is doubling down on TIGIT in a new deal with Agenus Inc. The company paid $200m upfront for exclusive global rights to the bispecific antibody AGEN1777, a handsome price for a drug that is still in preclinical development.
Bristol Pays Out $200m For Agenus' Preclinical Bispecific TIGIT
Agenus president Jennifer Buell talked to Scrip about partnering with Bristol and the dual nature approach of AGEN1777.
